# Veracyte, Inc. (VCYT)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/VCYT/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 289.39M | $ 54.20M | $ 75.22M | $ 40.11M | $ 1.39B |
| 2025 | $ 529.51M | $ 67.94M | $ 129.11M | $ 39.65M | $ 1.31B |
| 2024 | $ 468.53M | $ 25.37M | $ 67.07M | $ 50.74M | $ 1.18B |
| 2023 | $ 390.39M | $ -80.45M | $ 37.04M | $ 12.63M | $ 1.04B |
| 2022 | $ 331.26M | $ -40.84M | $ -1.13M | $ 14.72M | $ 1.08B |
| 2021 | $ 260.93M | $ -89.82M | $ -43.98M | $ 18.85M | $ 1.10B |
| 2020 | $ 149.67M | $ -44.47M | $ -15.99M | $ 12.32M | $ 421.23M |
| 2019 | $ 155.37M | $ -16.26M | $ -7.73M | $ 13.61M | $ 239.46M |
| 2018 | $ 121.51M | $ -30.37M | $ -20.33M | $ 25.28M | $ 79.76M |
| 2017 | $ 96.93M | $ -41.77M | $ -34.58M | $ 25.25M | $ 37.23M |
| 2016 | $ 89.55M | $ -43.14M | $ -44.29M | $ 25.52M | $ 59.58M |
| 2015 | $ 69.50M | $ -47.32M | $ -46.52M | $ 5.03M | $ 51.25M |
| 2014 | $ 53.96M | $ -41.50M | $ -41.90M | $ 4.92M | $ 41.37M |
| 2013 | $ 31.12M | $ -36.38M | $ -29.14M | $ 4.90M | $ 56.44M |
| 2012 | $ 11.09M | $ -14.11M | $ -14.40M | $ 0 | $ 4.90M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.03 |
| Liabilities / Eq | 0.07 |
| Current Ratio | 9.16 |

## Debt coverage

| Indicator | Value |
| --- | --- |
| Gross Debt / FCF | 2.39 |

## Other views

- [Metrics](https://sponda.capital/en/VCYT.md)
- [Charts](https://sponda.capital/en/VCYT/charts.md)
- [Compare](https://sponda.capital/en/VCYT/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-30.